The VCPIP1‐UBE3A Deubiquitination‐Ubiquitination Cascade Contributes to Castration‐Resistant Prostate Cancer Progression
- 1Department of Urology Urology Research Institute the First Affiliated Hospital Fujian Medical University Fuzhou China
- 2Department of Urology National Regional Medical Center Binhai Campus of the First Affiliated Hospital Fujian Medical University Fuzhou China
- 3Fujian Key Laboratory of Tumor Immunotherapy the First Affiliated Hospital Fujian Medical University Fuzhou China
Abstract
The molecular mechanisms underlying progression from metastatic hormone‐sensitive prostate cancer (mHSPC) to metastatic castration‐resistant prostate cancer (mCRPC) remain incompletely understood. Paired proteomic profiling of specimens from 10 patients identified VCPIP1 as a candidate regulator, and its clinical relevance was evaluated in an independent cohort of 128 mHSPC patients. Elevated VCPIP1 expression was independently associated with shorter CRPC‐free survival. Functional studies demonstrated that VCPIP1 promoted prostate cancer proliferation, migration, invasion, and metastasis in a deubiquitinase activity‐dependent manner. Mechanistically, VCPIP1 directly bound UBE3A and stabilized it by removing K48‐linked polyubiquitin chains at Lys711, thereby enhancing UBE3A‐mediated p53 ubiquitination and proteasomal degradation. Wild‐type UBE3A, but not its catalytically inactive C833A mutant, rescued the malignant phenotypes suppressed by VCPIP1 depletion. TP53 knockdown partially reversed these effects in TP53‐wild‐type LNCaP cells but not in TP53‐mutant DU145 cells, indicating a TP53 context‐dependent contribution of p53. VCPIP1 depletion also reduced androgen receptor expression in LNCaP cells and enhanced enzalutamide sensitivity in patient‐derived organoids. These findings identify a VCPIP1/UBE3A deubiquitination–ubiquitination cascade contributing to CRPC progression and support further investigation of VCPIP1 as a potential prognostic biomarker and therapeutic target.
Related
- m6A-Driven Intratumoral Cholesterol Biosynthesis Fuels Castration-Resistant Prostate Cancer Progression
- Peripheral blood mRNA-based prognostic model for progression to metastatic castration-resistant prostate cancer and identification of SLC6A8 as a glycolysis-promoting biomarker
- A low-androgen environment sustains redox-active sGC states required to restrain castration-resistant prostate cancer growth via elevated cGMP levels
- Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database
- Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer
BibTeX
@article{lin2026vcpip1ube3a,
title = {{The VCPIP1‐UBE3A Deubiquitination‐Ubiquitination Cascade Contributes to Castration‐Resistant Prostate Cancer Progression}},
author = {Fei Lin and Wen‐Cai Zheng and Yi‐Qiu Wang and Bin Lin and Yun‐Zhi Lin and Dong‐Ning Chen and Xiao‐Dong Li and Xue‐Yi Xue and Yong Wei and Ning Xu},
journal = {Advanced Science},
year = {2026},
month = oct,
doi = {10.1002/advs.78433},
url = {https://doi.org/10.1002/advs.78433},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The VCPIP1‐UBE3A Deubiquitination‐Ubiquitination Cascade Contributes to Castration‐Resistant Prostate Cancer Progression
AU - Fei Lin
AU - Wen‐Cai Zheng
AU - Yi‐Qiu Wang
AU - Bin Lin
AU - Yun‐Zhi Lin
AU - Dong‐Ning Chen
AU - Xiao‐Dong Li
AU - Xue‐Yi Xue
AU - Yong Wei
AU - Ning Xu
PY - 2026
DA - 2026/10/25
JO - Advanced Science
DO - 10.1002/advs.78433
UR - https://doi.org/10.1002/advs.78433
AB - The molecular mechanisms underlying progression from metastatic hormone‐sensitive prostate cancer (mHSPC) to metastatic castration‐resistant prostate cancer (mCRPC) remain incompletely understood. Paired proteomic profiling of specimens from 10 patients identified VCPIP1 as a candidate regulator, and its clinical relevance was evaluated in an independent cohort of 128 mHSPC patients. Elevated VCPIP1 expression was independently associated with shorter CRPC‐free survival. Functional studies demonstrated that VCPIP1 promoted prostate cancer proliferation, migration, invasion, and metastasis in a deubiquitinase activity‐dependent manner. Mechanistically, VCPIP1 directly bound UBE3A and stabilized it by removing K48‐linked polyubiquitin chains at Lys711, thereby enhancing UBE3A‐mediated p53 ubiquitination and proteasomal degradation. Wild‐type UBE3A, but not its catalytically inactive C833A mutant, rescued the malignant phenotypes suppressed by VCPIP1 depletion. TP53 knockdown partially reversed these effects in TP53‐wild‐type LNCaP cells but not in TP53‐mutant DU145 cells, indicating a TP53 context‐dependent contribution of p53. VCPIP1 depletion also reduced androgen receptor expression in LNCaP cells and enhanced enzalutamide sensitivity in patient‐derived organoids. These findings identify a VCPIP1/UBE3A deubiquitination–ubiquitination cascade contributing to CRPC progression and support further investigation of VCPIP1 as a potential prognostic biomarker and therapeutic target.
SN - 2198-3844
ER -